Mitomycin-C
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
Lung Cancer 2019 January [Link] Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, Guppy N, Borg E, Falzon M, Nankivell M, Nicholson AG, Janes SM Abstract Introduction BRCA1 associated protein-1 (BAP1) is a key tumor driver in mesothelioma and a potential biomarker predicting response to several targeted therapies in clinical testing. Whether it also modulates response to cytotoxic chemotherapy is undetermined. This study used…
Read MorePeritoneal Mesothelioma
Current Treatment Options in Oncology. 2008 Jun;9(2-3):180-90. Epub 2008 Oct 8. [Link] Hesdorffer ME, Chabot J, DeRosa C, Taub R. Mesothelioma Applied Research Foundation, Santa Barbara, CA, USA. mhesdorer@curemeso.org Abstract Opinion statement: Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that rapidly spreads within the confines of the abdominal cavity to involve most accessible peritoneal…
Read MoreActive symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
Lancet. 2008 May 17;371(9625):1685-1694. [Link] Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O’Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; on behalf of the MS01 Trial Management Group. Leeds General Infirmary, Leeds, UK. Abstract Background: Malignant pleural mesothelioma…
Read MoreCost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice
Value in Health. 2008 Jan-Feb;11(1):4-12. [Link] Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J. M-TAG Pty Ltd, A Unit of IMS Health, St Leonards, NSW, Australia. acordony@au.imshealth.com Abstract Objectives: Findings from the largest randomized phase III trial in patients with unresectable malignant pleural mesothelioma (EMPHACIS study; n = 448) were used to…
Read MoreThoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial
In Vivo. 2006 Nov-Dec;20(6A):715-8. [Link] Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G. Department of Surgical Sciences, University of L’Aquila, Italy. stefanoguadagni@interfree.it Abstract Malignant pleural mesothelioma (MPM) is an aggressive treatment-resistant tumor with a median survival from diagnosis of 12 months. Although multimodality protocols that combine aggressive surgery and…
Read MoreEfficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma
Cancer. 2007 Jan 1;109(1):93-9. [Link] Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew’s Hospital, West Smithfield, London, UK. Abstract Background: Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome…
Read More